UK markets closed

Elanco Animal Health Incorporated (ELAN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
16.28+0.11 (+0.68%)
At close: 04:00PM EDT
16.40 +0.12 (+0.74%)
After hours: 08:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close16.17
Open16.20
Bid16.30 x 1800
Ask16.31 x 1800
Day's range16.12 - 16.41
52-week range7.88 - 16.88
Volume2,193,393
Avg. volume4,410,577
Market cap8.026B
Beta (5Y monthly)1.30
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GuruFocus.com

    Director William Doyle Acquires 15,000 Shares of Elanco Animal Health Inc (ELAN)

    Elanco Animal Health Inc (NYSE:ELAN), a company specializing in the development, manufacturing, and marketing of products for animal health and production, has reported an insider purchase filed with the SEC.

  • Reuters

    UPDATE 1-Ancora seeks four board seats at Elanco amid push for changes

    Investment firm Ancora Holdings said it is pushing for four board seats at Elanco Animal Health and wants to replace the chief executive at the company that makes medicines and vaccinations for pets and livestock. Ancora nominated the director candidates, including one of the firm's executives, to Elanco's 12-person board and wants to oust CEO Jeffrey Simmons over what the activist investor calls poor performance. Elanco, which was spun out of pharmaceutical company Eli Lilly, is one of the world's leading developers and makers of animal health products and has a market value of $7.8 billion.

  • Reuters

    Ancora seeks four board seats at Elanco amid push for changes

    (Reuters) -Investment firm Ancora Holdings said it is pushing for four board seats at Elanco Animal Health and wants to replace the chief executive at the company that makes medicines and vaccinations for pets and livestock. Ancora nominated the director candidates, including one of the firm's executives, to Elanco's 12-person board and wants to oust CEO Jeffrey Simmons over what the activist investor calls poor performance. Elanco, which was spun out of pharmaceutical company Eli Lilly, is one of the world's leading developers and makers of animal health products and has a market value of $7.8 billion.